Studies of prophylactic salpingectomy specimens from BRCA1/2 mutation carriers, at risk for tubal and ovarian high-grade serous carcinoma (SerCa), have consistently revealed occult carcinomas and putative histological cancer precursors in the distal fallopian tube epithelium (FTE), supporting the FTE as the source of SerCa. In this thesis I molecularly characterized and compared non-malignant FTE from mutation carriers (FTEb) and control patients (FTEn) to identify alterations that may predispose to malignant transformation. Gene expression profiling of laser capture microdissected FTEn, FTEb and SerCa indicated that SerCa have similar molecular profiles whether of presumed ovarian or tubal origin, supporting the notion they share a common...
The pathogenesis of high-grade serous carcinoma of the ovary has come into sharper focus as closer a...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...
Germline or somatic mutation(s) in BRCA1 is associated with a 40-50% lifetime risk of developing hig...
SummaryHigh-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges....
SummaryHigh-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges....
AbstractMicroinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered wi...
Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the...
AbstractAlthough controversial, recent studies suggest that serous ovarian carcinomas may arise from...
Germline BRCA1 or BRCA2 mutations (mtBRCA1 and mtBRCA2) increase risk for high-grade serous ovarian ...
Recent evidence indicates high-grade serous ovarian cancer originates from the fallopian tube epithe...
High grade serous ovarian cancer (HGSC), the most lethal and frequent type of epithelial ovarian can...
Background: High-grade serous carcinoma (HGSC) is the most frequent and lethal type of ovarian cance...
Although controversial, recent studies suggest that serous ovarian carcinomas may arise from fallopi...
AbstractAlthough controversial, recent studies suggest that serous ovarian carcinomas may arise from...
The pathogenesis of high-grade serous carcinoma of the ovary has come into sharper focus as closer a...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...
Germline or somatic mutation(s) in BRCA1 is associated with a 40-50% lifetime risk of developing hig...
SummaryHigh-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges....
SummaryHigh-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges....
AbstractMicroinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered wi...
Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the...
AbstractAlthough controversial, recent studies suggest that serous ovarian carcinomas may arise from...
Germline BRCA1 or BRCA2 mutations (mtBRCA1 and mtBRCA2) increase risk for high-grade serous ovarian ...
Recent evidence indicates high-grade serous ovarian cancer originates from the fallopian tube epithe...
High grade serous ovarian cancer (HGSC), the most lethal and frequent type of epithelial ovarian can...
Background: High-grade serous carcinoma (HGSC) is the most frequent and lethal type of ovarian cance...
Although controversial, recent studies suggest that serous ovarian carcinomas may arise from fallopi...
AbstractAlthough controversial, recent studies suggest that serous ovarian carcinomas may arise from...
The pathogenesis of high-grade serous carcinoma of the ovary has come into sharper focus as closer a...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...
Germline BRCA1 or BRCA2 mutation carriers (mtBRCA1 and mtBRCA2) are at increased risk for high-grade...